Hamburg, Germany, June 5, 2019 — Evotec SE announced that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $9.0 m to Evotec.
Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one programme into lead optimisation as well as including additional cell lines and now a new cell type. [Read more…]